Unsupervised HLA peptidome deconvolution improves ligand prediction accuracy and predicts cooperative effects in peptide-HLA interactions

Journal of Immunology

Volumn 197, Issue 6, 2016, Pages 2492-2499

  Bassani Sternberg, Michal ^a,b   Gfeller, David ^b,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; PEPTIDE; HLA ANTIGEN CLASS 1; LIGAND; PEPTIDOMIMETIC AGENT; PROTEIN BINDING;

ALGORITHM; ARTICLE; B LYMPHOCYTE; BINDING SITE; CONTROLLED STUDY; MASS SPECTROMETRY; MATHEMATICAL MODEL; MEASUREMENT ACCURACY; PEPTIDOMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; BIOLOGY; CHEMISTRY; HUMAN; IMMUNOLOGY; METABOLISM;

ALGORITHMS; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; COMPUTATIONAL BIOLOGY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIGANDS; MASS SPECTROMETRY; PEPTIDES; PEPTIDOMIMETICS; PROTEIN BINDING;

EID: 84988940043     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600808     Document Type: Article

References (41)

1. Herr, W., E. Ranieri, A. Gambotto, L. S. Kierstead, A. A. Amoscato, L. Gesualdo, and W. J. Storkus. 1999. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc. Natl. Acad. Sci. USA 96: 12033-12038.
2. Shiga, H., T. Shioda, H. Tomiyama, Y. Takamiya, S. Oka, S. Kimura, Y. Yamaguchi, T. Gojoubori, H.-G. Rammensee, K. Miwa, and M. Takiguchi. 1996. Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS 10: 1075-1083.
3. Baumgaertner, P., N. Rufer, E. Devevre, L. Derré, D. Rimoldi, C. Geldhof, V. Voelter, D. Liénard, P. Romero, and D. E. Speiser. 2006. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res. 66: 1912-1916.
4. Snyder, A., V. Makarov, T. Merghoub, J. Yuan, J. M. Zaretsky, A. Desrichard, L. A. Walsh, M. A. Postow, P. Wong, T. S. Ho, et al. 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371: 2189-2199.
5. Van Allen, E. M., D. Miao, B. Schilling, S. A. Shukla, C. Blank, L. Zimmer, A. Sucker, U. Hillen, M. H. Geukes Foppen, S. M. Goldinger, et al. 2015. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350: 207-211.
6. Rizvi, N. A., M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. J. Havel, W. Lee, J. Yuan, P. Wong, T. S. Ho, et al. 2015. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124-128.
7. Le, D. T., J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling, A. D. Eyring, A. D. Skora, B. S. Luber, N. S. Azad, D. Laheru, et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372: 2509-2520.
8. Andreatta, M., and M. Nielsen. 2016. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32: 511-517.
9. Nielsen, M., C. Lundegaard, T. Blicher, K. Lamberth, M. Harndahl, S. Justesen, G. Røder, B. Peters, A. Sette, O. Lund, and S. Buus. 2007. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and-B locus protein of known sequence. PLoS One 2: e796.
10. Nielsen, M., C. Lundegaard, P. Worning, S. L. Lauemøller, K. Lamberth, S. Buus, S. Brunak, and O. Lund. 2003. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12: 1007-1017.
11. Peters, B., and A. Sette. 2005. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6: 132.
12. Neefjes, J., M. L. M. Jongsma, P. Paul, and O. Bakke. 2011. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11: 823-836.
13. Yadav, M., S. Jhunjhunwala, Q. T. Phung, P. Lupardus, J. Tanguay, S. Bumbaca, C. Franci, T. K. Cheung, J. Fritsche, T. Weinschenk, et al. 2014. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515: 572-576.
14. McGranahan, N., A. J. S. Furness, R. Rosenthal, S. Ramskov, R. Lyngaa, S. K. Saini, M. Jamal-Hanjani, G. A. Wilson, N. J. Birkbak, C. T. Hiley, et al. 2016. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351: 1463-1469.
15. Giam, K., R. Ayala-Perez, P. T. Illing, R. B. Schittenhelm, N. P. Croft, A. W. Purcell, and N. L. Dudek. 2015. A comprehensive analysis of peptides presented by HLA-A1. Tissue Antigens 85: 492-496.
16. Schittenhelm, R. B., N. L. Dudek, N. P. Croft, S. H. Ramarathinam, and A. W. Purcell. 2014. A comprehensive analysis of constitutive naturally processed and presented HLA-C04:01 (Cw4)-specific peptides. Tissue Antigens 83: 174-179.
17. Caron, E., D. J. Kowalewski, C. Chiek Koh, T. Sturm, H. Schuster, and R. Aebersold. 2015. Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry. Mol. Cell. Proteomics 14: 3105-3117.
18. Gubin, M. M., X. Zhang, H. Schuster, E. Caron, J. P. Ward, T. Noguchi, Y. Ivanova, J. Hundal, C. D. Arthur, W.-J. Krebber, et al. 2014. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515: 577-581.
19. Caron, E., L. Espona, D. J. Kowalewski, H. Schuster, N. Ternette, A. Alpízar, R. B. Schittenhelm, S. H. Ramarathinam, C. S. Lindestam Arlehamn, C. Chiek Koh, et al. 2015. An open-source computational and data resource to analyze digital maps of immunopeptidomes. eLife 4: e07661. O111.011833. doi:10.7554/ eLife.07661.
20. Andreatta, M., O. Lund, and M. Nielsen. 2013. Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach. Bioinformatics 29: 8-14.
21. Bassani-Sternberg, M., S. Pletscher-Frankild, L. J. Jensen, and M. Mann. 2015. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell. Proteomics 14: 658-673.
22. Mommen, G. P. M., F. Marino, H. D. Meiring, M. C. M. Poelen, J. A. M. van Gaans-van den Brink, S. Mohammed, A. J. R. Heck, and C. A. C. M. van Els. 2016. Sampling from the proteome to the human leukocyte antigen-DR (HLADR) ligandome proceeds via high specificity. Mol. Cell. Proteomics 15: 1412-1423.
23. Ritz, D., A. Gloger, B. Weide, C. Garbe, D. Neri, and T. Fugmann. 2016. Highsensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera. Proteomics 16: 1570-1580.
24. Gfeller, D., F. Butty, M. Wierzbicka, E. Verschueren, P. Vanhee, H. Huang, A. Ernst, N. Dar, I. Stagljar, L. Serrano, et al. 2011. The multiple-specificity landscape of modular peptide recognition domains. Mol. Syst. Biol. 7: 484.
25. Kim, T., M. S. Tyndel, H. Huang, S. S. Sidhu, G. D. Bader, D. Gfeller, and P. M. Kim. 2012. MUSI: an integrated system for identifying multiple specificity from very large peptide or nucleic acid data sets. Nucleic Acids Res. 40: e47.
26. Bailey, T. L., and C. Elkan. 1995. The value of prior knowledge in discovering motifs with MEME. Proc. Int. Conf. Intell. Syst. Mol. Biol. 3: 21-29.
27. Mommen, G. P. M., C. K. Frese, H. D. Meiring, J. van Gaans-van den Brink, A. P. J. M. de Jong, C. A. C. M. van Els, and A. J. R. Heck. 2014. Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD). Proc. Natl. Acad. Sci. USA 111: 4507-4512.
28. Vita, R., J. A. Overton, J. A. Greenbaum, J. Ponomarenko, J. D. Clark, J. R. Cantrell, D. K. Wheeler, J. L. Gabbard, D. Hix, A. Sette, and B. Peters. 2015. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 43: D405-D412.
29. Rasmussen, M., M. Harndahl, A. Stryhn, R. Boucherma, L. L. Nielsen, F. A. Lemonnier, M. Nielsen, and S. Buus. 2014. Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule. J. Immunol. 193: 4790-4802.
30. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanović. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
31. Reche, P. A., and E. L. Reinherz. 2007. Prediction of peptide-MHC binding using profiles. Methods Mol. Biol. 409: 185-200.
32. Garboczi, D. N., D. T. Hung, and D. C. Wiley. 1992. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl. Acad. Sci. USA 89: 3429-3433.
33. Caron, E., K. Vincent, M.-H. Fortier, J.-P. Laverdure, A. Bramoullé, M.-P. Hardy, G. Voisin, P. P. Roux, S. Lemieux, P. Thibault, and C. Perreault. 2011. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol. Syst. Biol. 7: 533.
34. Andreatta, M., E. Karosiene, M. Rasmussen, A. Stryhn, S. Buus, and M. Nielsen. 2015. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics 67: 641-650.
35. Trolle, T., C. P. McMurtrey, J. Sidney, W. Bardet, S. C. Osborn, T. Kaever, A. Sette, W. H. Hildebrand, M. Nielsen, and B. Peters. 2016. The length distribution of class I-restricted T cell epitopes is determined by both peptide supply and MHC allele-specific binding preference. J. Immunol. 196: 1480-1487.
36. McMurtrey, C., T. Trolle, T. Sansom, S. G. Remesh, T. Kaever, W. Bardet, K. Jackson, R. McLeod, A. Sette, M. Nielsen, et al. 2016. Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. eLife 5: 246.
37. Nielsen, M., and M. Andreatta. 2016. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 8: 33.
38. Du, V. Y., A. Bansal, J. Carlson, J. F. Salazar-Gonzalez, M. G. Salazar, K. Ladell, S. Gras, T. M. Josephs, S. L. Heath, D. A. Price, et al. 2016. HIV-1-specific CD8 T cells exhibit limited cross-reactivity during acute infection. J. Immunol. 196: 3276-3286.
39. Schittenhelm, R. B., T. C. C. L. K. Sian, P. G. Wilmann, N. L. Dudek, and A. W. Purcell. 2015. Revisiting the arthritogenic peptide theory: quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes. Arthritis Rheumatol. 67: 702-713.
40. Kløverpris, H. N., D. K. Cole, A. Fuller, J. Carlson, K. Beck, A. J. Schauenburg, P. J. Rizkallah, S. Buus, A. K. Sewell, and P. Goulder. 2015. A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape. Retrovirology 12: 20
41. Brennan, R. M., J. Petersen, M. A. Neller, J. J. Miles, J. M. Burrows, C. Smith, J. McCluskey, R. Khanna, J. Rossjohn, and S. R. Burrows. 2012. The impact of a large and frequent deletion in the human TCR β locus on antiviral immunity. J. Immunol. 188: 2742-2748.